CORDIS
EU research results

CORDIS

English EN

Decision-making within cells and differentiation entity therapies

Project information

Grant agreement ID: 315902

Status

Closed project

  • Start date

    1 March 2013

  • End date

    28 February 2017

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 3 313 022,02

  • EU contribution

    € 3 313 022,02

Coordinated by:

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

Objective

"Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiation therapy. This type of therapy aims, using only mildly toxic treatments, to induce terminal maturation of leukaemia cells and accelerate their death. WP2 responds to the urgent need to devise milder treatments, especially for older and frailer AML patients. Participants have already identified a number of promising new therapeutic agents. Working across these two complementary areas will train our Early Stage Researchers (ESR) to understand the translation of new fundamental science into the development of new therapies. The ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy, so will provide an excellent scientific training in these areas. Secondments/visits by ESRs to participants who run centres of expertise in leading edge technologies will provide training in these; and the time spent with private sector participants, and the courses they provide, will ensure that ESRs acquire the transferable skills they will need if they are to work well in, and build bridges between, commercial and publicly funded research organisations. ESRs will also receive management training. This research and training, which will develop our ESRs as versatile scientists, will involve the combined efforts of prestigious research institutes and universities, Poland’s leading governmental pharmaceutical R & D institute, two successful biopharmaceutical companies and a leading management consultancy."

Coordinator

THE UNIVERSITY OF BIRMINGHAM

Address

Edgbaston
B15 2tt Birmingham

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 753 274,50

Administrative Contact

May Chung (Ms.)

Participants (7)

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland

EU Contribution

€ 550 419,30

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 496 573,88

UNIWERSYTET WROCLAWSKI

Poland

EU Contribution

€ 249 205,66

ORBSEN THERAPEUTICS LIMITED

Ireland

EU Contribution

€ 244 814,45

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 285 056,62

SIEC BADAWCZA LUKASIEWICZ - INSTYTUT FARMACEUTYCZNY

Poland

EU Contribution

€ 448 620,90

CELENTYX LIMITED

United Kingdom

EU Contribution

€ 285 056,62

Project information

Grant agreement ID: 315902

Status

Closed project

  • Start date

    1 March 2013

  • End date

    28 February 2017

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 3 313 022,02

  • EU contribution

    € 3 313 022,02

Coordinated by:

THE UNIVERSITY OF BIRMINGHAM

United Kingdom